NSCLC

[Cell Death & Disease] Researchers identified neurokinin-1 as a significantly upregulated GPCR in the transcriptome and tissue array of human lung cancer samples, associated with advanced clinical stages and poor prognosis.

[Expert Review of Anticancer Therapy] Scientists assess and discuss the available data concerning chemo-immunotherapy combinations in the treatment of naïve advanced NSCLC, as well as presenting the most promising data involving combinations currently under investigation.

[Thoracic Cancer] Expression levels of circ_0007385, microRNA-493-3p (miR-493-3p) and Ras-related protein Rab-22A (RAB22A) were detected by quantitative real-time polymerase chain reaction (qRT-PCR) in NSCLC tissues and cells.

[Biochemical Genetics] The authors investigated the role of circular RNA F-box and WD repeat domain containing 8 (circFBXW8) in NSCLC progression and the underlying mechanism.

[Genprex, Inc.] Genprex, Inc. announced that the FDA has granted Fast Track Designation for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck & Co’s Keytruda® in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer whose disease progressed after treatment with Keytruda.

[Scientific Reports] Researchers determined the PPARδ and miR-17 expression profiles in NSCLC and to assess their diagnostic value in lung carcinogenesis.